Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection

Mario A Martinez; Ting-Yi Chen; Hosoon Choi; Munok Hwang; Dhammika Navarathna; Linhue Hao; Michael Gale Jr; Gregory Camus; Hector E Ramirez; Chetan Jinadatha

doi:10.1093/ofid/ofac382

Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection

Open Forum Infect Dis. 2022 Jul 29;9(8):ofac382. doi: 10.1093/ofid/ofac382. eCollection 2022 Aug.

Authors

Affiliations

¹ Division of Infectious Diseases, Baylor Scott and White Health, Temple, Texas, USA.
² Department of Medicine, Central Texas Veterans Health Care System, Temple, Texas, USA.
³ Department of Research, Central Texas Veterans Health Care System, Temple, Texas, USA.
⁴ Department of Microbiology and Pathology, Central Texas Veterans Health Care System, Temple, Texas, USA.
⁵ Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA.
⁶ Gilead Sciences, Inc, Foster City, California, USA.

Abstract

Persistent severe acute respiratory syndrome coronavirus 2 infection is difficult to treat. Here, we report a case of 5-month persistent coronavirus disease 2019 in an immunocompromised patient who was successfully treated with 30 consecutive days of remdesivir. Prolonged remdesivir infusion with concurrent cycle threshold monitoring might provide a potential solution to cure these patients with difficult-to-treat infections.

Keywords: Ct value; persistent COVID-19; prolonged remdesivir; remdesivir mutation; remdesivir resistance.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Abstract

Grants and funding